More news
- Axalta releases Q1 2024 results
- PPG again earns EcoVadis gold rating for sustainability practices, ranking among top 7% of...
- Baikowski® France 2030 plan winner for its innovative project to decarbonise alumina prod...
- New CEO at BASF: Martin Brudermüller hands over to Markus Kamieth
- Wacker stays below prior-year figures amid lower selling prices in Q1
Royal DSM reported Q2 2014 EBITDA from continuing operations of €293M compared to €332M in Q2 2013 and €272M in Q1 2014. Nutrition showed improvement compared to the last two quarters. Performance Materials continued its encouraging underlying trend and delivered higher results. Polymer Intermediates was negatively impacted by lower caprolactam margins.
Commenting on the results, Feike Sijbesma, CEO/ Chairman of the DSM Managing Board, said: "DSM delivered improved results versus the first quarter, despite persistent currency headwinds. Performance Materials saw continued positive momentum in a number of end-markets, whereas Polymer Intermediates has seen weaker business conditions for caprolactam.